Item 4. Mine Safety Disclosures.

5K characters. Original on sec.gov · Markdown

Item 4. Mine Safety Disclosures.

Not Applicable.

Executive Officers of the Registrant (ages as of February 1, 2022)

All officers listed below serve at the pleasure of the Board of Directors. None of these officers was elected pursuant to any arrangement or understanding between the officer and any other person(s).


Name	Age	Offices and Business Experience
Robert M. Davis	55	Chief Executive Officer and President (since July 2021); Executive Vice President, Global Services, and Chief Financial Officer (since April 2016)
Sanat Chattopadhyay	62	Executive Vice President and President, Merck Manufacturing Division (since March 2016)
Richard R. DeLuca, Jr.	59	Executive Vice President and President, Merck Animal Health (since September 2011)
Cristal Downing	53	Executive Vice President and Chief Communications & Public Affairs Officer (since August 2021); Vice President Medical Devices, Global Communications and Public Affairs Johnson & Johnson (December 2020-August 2021); Vice President Financial Communication, Johnson & Johnson (January 2018-December 2020); Prior to that, Senior Director Communications at Johnson & Johnson
Kenneth C. Frazier	67	Executive Chairman (since July 2021); Prior to that, Chairman, President and Chief Executive Officer
Julie L. Gerberding	65	Executive Vice President and Chief Patient Officer, Population Health and Sustainability (since July 2016)
Rita A. Karachun	58	Senior Vice President Finance - Global Controller (since March 2014)
Michael A. Klobuchar	46	Executive Vice President, Chief Strategy Officer (since July 2021); Senior Vice President, CFO of Merck R&D and Head of Global Portfolio and Alliance Management (January 2019-June 2021); Senior Vice President of Corporate Strategy and Planning and President of Emerging Businesses (December 2017-January 2019); Prior to that, Vice President, Global Business and Financial Planning
Lisa LeCointe-Cephas	40	Senior Vice President, Chief Ethics and Compliance Officer (since April 2021); Executive Director, Head of Global Investigations (February 2018 – April 2021); Prior to that, Senior Counsel, Litigation and Government Investigations, Bristol-Myers Squibb Company
Dean Li	59	President, Merck Research Laboratories (since January 2021); Senior Vice President, Discovery Sciences and Translational Medicine, Merck Research Laboratories (November 2017-January 2021); Vice President, Translational Medicine (March 2017-November 2017); Prior to that, Chief Scientific Officer and Associate Vice President, University of Utah Health Sciences
Caroline Litchfield	53	Executive Vice President and Chief Financial Officer (since April 2021); Senior Vice President, Corporate Treasurer (January 2018-March 2021); Prior to that, Senior Vice President, Global Human Health
Steven C. Mizell	61	Executive Vice President, Chief Human Resources Officer (since December 2016)
David M. Williams	53	Executive Vice President, Chief Information and Digital Officer (Since August 2020); Acting Chief Information and Digital Officer (December 2019-August 2020); Vice President and Chief Information Officer, Merck Animal Health (May 2017-December 2019); Prior to that, Associate Vice President and Chief Information Officer, Merck Animal Health
Jennifer Zachary	44	Executive Vice President, General Counsel and Corporate Secretary (since January 2020); Executive Vice President and General Counsel (April 2018-January 2020); Prior to that, Partner, Covington & Burling LLP

Table o f Contents

On February 16, 2022, the Company announced that Ms. Arpa Garay will lead Human Health Global Marketing and Mr. Jannie Oosthuizen will lead U.S. Human Health. Both Ms. Garay and Mr. Oosthuizen will become Executive Officers of the Company, effective February 28, 2022.


Name	Age	Offices and Business Experience
Arpa Garay	43	President, Global Oncology and Digital (since January 2022); President, Global Pharmaceuticals, Commercial Analytics, Digital Marketing (March 2019-January 2022); Senior Vice President, U.S. Vaccines Business Unit (June 2017-March 2019); Prior to that, Managing Director MSD, Norway
Jannie Oosthuizen	54	Senior Vice President and President Merck U.S. Human Health (since January 2022); Senior Vice President and Head of Global Oncology Commercial (January 2021-December 2021); Senior Vice President and President of MSD K.K. (July 2016-December 2020)

Table o f Contents

PART II

Previous: Item 3. Legal Proceedings. · Next: Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.